Company / EPS (Diluted)
Supernus Pharmaceuticals, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$0.02
FY2025
5-year range
$0.02 / $2.36
FY2021-FY2025
Trend
-98.1%
vs FY2024
Sector context
#49 of 204
Health Care
What the data says
Supernus Pharmaceuticals, Inc.'s eps (diluted) of $0.02 is higher than 76% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-0.26 in FY2016 to $2.36 in FY2022.
Based on SEC 10-K filings.
0.02 in FY2025 with a 5-year CAGR of -60.4%. Top quartile in the Health Care sector.
Remained stable around $0.02 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -79.6%
- 5-Year CAGR
- -60.4%
- 10-Year CAGR
- -
Sector benchmark
+102.3% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 98.1% year-over-year.
- Ranks #49 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.02 | -98.1% |
| FY2024 | $1.04 | +5100.0% |
| FY2023 | $0.02 | -99.2% |
| FY2022 | $2.36 | +12.4% |
| FY2021 | $2.10 | +2.4% |
| FY2020 | $2.05 | +89.8% |
| FY2019 | $1.08 | -38.6% |
| FY2018 | $1.76 | +528.6% |
| FY2017 | $0.28 | +207.7% |
| FY2016 | -$0.26 | +91.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026